In the K562 CML-derived cell line, the CRISPR-Trap system disrupted the BCR/ABL sequence, entirely preventing any oncogenic effect on in vitro survival and proliferation in selected Venus fluorescent cells in the CRISPR/Cas9-mediated group. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.